Deciphera Pharmaceuticals (NASDAQ:DCPH) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday, January 3rd.

A number of other equities research analysts also recently weighed in on DCPH. Instinet assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $57.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “overweight” rating and a $30.00 price target on the stock. JMP Securities started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued an “outperform” rating and a $38.00 target price on the stock. Nomura started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Piper Jaffray Companies initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $40.83.

Deciphera Pharmaceuticals (DCPH) opened at $26.22 on Wednesday. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $28.96.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($5.85) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($5.30). sell-side analysts expect that Deciphera Pharmaceuticals will post -2.91 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Emerald Advisers Inc. PA bought a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at about $6,661,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at about $5,548,000. Kornitzer Capital Management Inc. KS acquired a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $2,172,000. SG Americas Securities LLC acquired a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $143,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $1,424,000. 44.01% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Deciphera Pharmaceuticals (NASDAQ:DCPH) Lifted to Hold at BidaskClub” was first reported by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.mareainformativa.com/deciphera-pharmaceuticals-dcph-lifted-to-hold-at-bidaskclub-updated-updated-updated/126520/.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.